Genzyme Goes Mainstream
By Business Review Editor
Pharma Deals Review: Vol 2008 Issue 92 (Table of Contents)
Published: 1 Feb-2008
DOI: 10.3833/pdr.v2008.i92.219 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
Genzyme has broken away from its niche market model in its agreement with Isis Pharmaceuticals for mipomersen, an antisense drug for high-risk cardiovascular (hypercholesterolaemic) patients, for which Genzyme has acquired an exclusive worldwide licence for a headline-grabbing US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS